Caris Life Sciences and Threshold Pharma collaborate to utilize Caris' ADAPT biotargeting
Caris Life Sciences and Threshold Pharmaceuticals announced a development and commercialization agreement to utilize Caris' patented and proprietaryADAPT Biotargeting System™ to develop a tissue-based clinical diagnostic assay for pancreatic cancer patients. October 25, 2016